Anjian Xu

1.4k total citations
53 papers, 941 citations indexed

About

Anjian Xu is a scholar working on Molecular Biology, Hematology and Nutrition and Dietetics. According to data from OpenAlex, Anjian Xu has authored 53 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 12 papers in Hematology and 12 papers in Nutrition and Dietetics. Recurrent topics in Anjian Xu's work include Trace Elements in Health (12 papers), Iron Metabolism and Disorders (12 papers) and Liver Disease Diagnosis and Treatment (10 papers). Anjian Xu is often cited by papers focused on Trace Elements in Health (12 papers), Iron Metabolism and Disorders (12 papers) and Liver Disease Diagnosis and Treatment (10 papers). Anjian Xu collaborates with scholars based in China, United States and France. Anjian Xu's co-authors include Wei Chen, Jian Huang, Aiting Yang, Hong You, Yanmeng Li, Dacheng He, Xueyuan Xiao, Gui-fang Zhu, Y Wang and Jinqian Liang and has published in prestigious journals such as Oncogene, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Anjian Xu

53 papers receiving 935 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anjian Xu China 18 547 173 167 166 149 53 941
N. Lale Şatıroğlu-Tufan Türkiye 18 571 1.0× 191 1.1× 169 1.0× 94 0.6× 134 0.9× 42 997
Torsten Wüestefeld Germany 13 579 1.1× 246 1.4× 237 1.4× 195 1.2× 150 1.0× 26 1.1k
Chung-Ta Lee Taiwan 15 420 0.8× 197 1.1× 307 1.8× 80 0.5× 124 0.8× 37 866
Yanlin Huang China 16 443 0.8× 151 0.9× 219 1.3× 56 0.3× 119 0.8× 64 815
Friederike Böhm Switzerland 13 496 0.9× 127 0.7× 148 0.9× 383 2.3× 188 1.3× 15 1.0k
Xi‐Dai Long China 22 793 1.4× 190 1.1× 480 2.9× 101 0.6× 144 1.0× 65 1.2k
Alicia M. Cole United Kingdom 10 681 1.2× 379 2.2× 151 0.9× 264 1.6× 140 0.9× 15 1.2k
Kira Bettermann Austria 9 545 1.0× 125 0.7× 424 2.5× 240 1.4× 301 2.0× 11 983
Ming-hua Zhu China 21 833 1.5× 289 1.7× 461 2.8× 110 0.7× 169 1.1× 50 1.2k
Carl Bart Rountree United States 17 569 1.0× 359 2.1× 197 1.2× 290 1.7× 118 0.8× 20 1.0k

Countries citing papers authored by Anjian Xu

Since Specialization
Citations

This map shows the geographic impact of Anjian Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjian Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjian Xu more than expected).

Fields of papers citing papers by Anjian Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjian Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjian Xu. The network helps show where Anjian Xu may publish in the future.

Co-authorship network of co-authors of Anjian Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Anjian Xu. A scholar is included among the top collaborators of Anjian Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjian Xu. Anjian Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yanmeng, Anjian Xu, Susu Liu, et al.. (2024). SUGP2 p.(Arg639Gln) variant is involved in the pathogenesis of hemochromatosis via the CIRBP/BMPER signaling pathway. American Journal of Hematology. 99(9). 1691–1703. 1 indexed citations
2.
Zhang, Ning, Xiaoning Wu, Yameng Sun, et al.. (2024). Targeting thrombospondin-2 retards liver fibrosis by inhibiting TLR4-FAK/TGF-β signaling. JHEP Reports. 6(3). 101014–101014. 8 indexed citations
3.
Zhang, Ning, Yanmeng Li, Qin Ouyang, et al.. (2024). Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 3 indexed citations
4.
Li, Yanmeng, Anjian Xu, Qin Ouyang, et al.. (2023). DENND3 p.L708V activating variant is involved in the pathogenesis of hereditary hemochromatosis via the RAB12/TFR2 signaling pathway. Hepatology International. 17(3). 648–661. 3 indexed citations
5.
Zhang, Wei, Yanmeng Li, Anjian Xu, et al.. (2022). Identification of novel non-HFE mutations in Chinese patients with hereditary hemochromatosis. Orphanet Journal of Rare Diseases. 17(1). 216–216. 5 indexed citations
6.
Li, Yanmeng, Qin Ouyang, Zhibin Chen, et al.. (2022). Intracellular labile iron is a key regulator of hepcidin expression and iron metabolism. Hepatology International. 17(3). 636–647. 11 indexed citations
7.
Ouyang, Qin, et al.. (2021). GTF2H2 Affects the Proliferation and Migration of Hep3B Hepatocellular Carcinoma Cells by Mediating AKT Signal Pathway. Zhongguo shengwu gongcheng zazhi. 41(6). 4–12. 1 indexed citations
8.
Wu, Liyan, Wei Zhang, Yanmeng Li, et al.. (2021). Correlation of genotype and phenotype in 32 patients with hereditary hemochromatosis in China. Orphanet Journal of Rare Diseases. 16(1). 398–398. 7 indexed citations
9.
Wu, Lina, Yanmeng Li, Yi Song, et al.. (2020). A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China. Orphanet Journal of Rare Diseases. 15(1). 74–74. 13 indexed citations
10.
Sun, Lan, Xiaona Zhou, Yanmeng Li, et al.. (2020). KLF5 regulates epithelial-mesenchymal transition of liver cancer cells in the context of p53 loss through miR-192 targeting of ZEB2. Cell Adhesion & Migration. 14(1). 182–194. 11 indexed citations
11.
Ren, Zhenggang, Jia Fan, Jian Xu, et al.. (2020). LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2. Annals of Oncology. 31. S1287–S1287. 25 indexed citations
12.
Zhang, Wei, Xiaomin Wang, Weijia Duan, et al.. (2020). HFE-Related Hemochromatosis in a Chinese Patient: The First Reported Case. Frontiers in Genetics. 11. 77–77. 7 indexed citations
13.
Zhao, Wenshan, Aiting Yang, Wei Chen, et al.. (2018). Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(4). 1129–1137. 68 indexed citations
14.
Li, Xiaojin, et al.. (2018). Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(5). 1693–1701. 20 indexed citations
15.
Xu, Anjian, et al.. (2017). Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. Annals of Oncology. 28. v12–v12. 3 indexed citations
16.
17.
Xu, Anjian, Yanmeng Li, Wenshan Zhao, et al.. (2017). PHP14 regulates hepatic stellate cells migration in liver fibrosis via mediating TGF-β1 signaling to PI3Kγ/AKT/Rac1 pathway. Journal of Molecular Medicine. 96(2). 119–133. 26 indexed citations
18.
Xu, Anjian & Junchao Gu. (2010). The current situation and the prevalent trend of cysticercosis in China.. 10(2). 239–240. 2 indexed citations
19.
Xu, Anjian, Jia Hao, Zhao Zhang, et al.. (2009). 14-kDa phosphohistidine phosphatase and its role in human lung cancer cell migration and invasion. Lung Cancer. 67(1). 48–56. 38 indexed citations
20.
Tian, Tian, Jia Hao, Anjian Xu, et al.. (2007). Determination of metastasis‐associated proteins in non‐small cell lung cancer by comparative proteomic analysis. Cancer Science. 98(8). 1265–1274. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. Lale Şatıroğlu-Tufan Breakdown of academic impact, for papers by Torsten Wüestefeld Breakdown of academic impact, for papers by Chung-Ta Lee Breakdown of academic impact, for papers by Yanlin Huang Breakdown of academic impact, for papers by Friederike Böhm Breakdown of academic impact, for papers by Xi‐Dai Long Breakdown of academic impact, for papers by Alicia M. Cole Breakdown of academic impact, for papers by Kira Bettermann Breakdown of academic impact, for papers by Ming-hua Zhu Breakdown of academic impact, for papers by Carl Bart Rountree
Rankless by CCL
2026